LY3202328 + Placebo + Atorvastatin + Simvastatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemias
Conditions
Dyslipidemias
Trial Timeline
Mar 1, 2016 → Feb 15, 2017
NCT ID
NCT02714569About LY3202328 + Placebo + Atorvastatin + Simvastatin
LY3202328 + Placebo + Atorvastatin + Simvastatin is a phase 1 stage product being developed by Eli Lilly for Dyslipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT02714569. Target conditions include Dyslipidemias.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02714569 | Phase 1 | Completed |
Competing Products
15 competing products in Dyslipidemias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mg | Yuhan | Approved | 85 |
| LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SC | Eli Lilly | Phase 1 | 33 |
| LY3885125 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3561774 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2484595 + Placebo + Atorvastatin | Eli Lilly | Phase 2 | 52 |
| Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| Vupanorsen + Placebo | Pfizer | Phase 2 | 51 |
| Atorvastatin | Pfizer | Approved | 84 |
| Atorvastatin + Atorvastatin + Atorvastatin | Pfizer | Approved | 84 |
| GWP42003 + GWP42003 + GWP42004 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| ARO-ANG3 + sterile normal saline (0.9% NaCl) | Arrowhead Pharmaceuticals | Phase 1 | 30 |